Literature DB >> 23582304

A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Janet L Douglas1, Ying Bai, Jean K Gustin, Ashlee V Moses.   

Abstract

We have undertaken a genetic strategy to map Vpu regions necessary for BST-2 antagonism and viral egress. This approach is based on our identification of an egress-defective Vpu variant encoded by an HIV-1 subtype C strain. We constructed a series of chimeric Vpu molecules made from the Vpu C variant and Vpu B from a standard laboratory strain. The TM domain from the inactive Vpu C, which contains multiple non-conserved residues, was responsible for a significant decrease in egress activity and BST-2 downregulation, confirming the functional importance of the Vpu TM domain. However, for complete inactivation, both the N-terminus and TM domain from the inactive Vpu C molecule were required, suggesting a new role for the Vpu N-terminus. In addition, determinants in the C-terminus of Vpu B that may be involved in efficient TGN accumulation were also necessary for enhanced viral egress but are missing or non-functional in Vpu C.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582304      PMCID: PMC3760674          DOI: 10.1016/j.virol.2013.03.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  68 in total

1.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation.

Authors:  F Margottin; S Benichou; H Durand; V Richard; L X Liu; E Gomas; R Benarous
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

3.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.

Authors:  Yukie Iwabu; Masanobu Kinomoto; Masashi Tatsumi; Hideaki Fujita; Mari Shimura; Yoshitaka Tanaka; Yukihito Ishizaka; David Nolan; Simon Mallal; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

5.  SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box.

Authors:  C Bai; P Sen; K Hofmann; L Ma; M Goebl; J W Harper; S J Elledge
Journal:  Cell       Date:  1996-07-26       Impact factor: 41.582

6.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

8.  Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.

Authors:  Andrey A Tokarev; Jason Munguia; John C Guatelli
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

9.  The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.

Authors:  Katy Janvier; Annegret Pelchen-Matthews; Jean-Baptiste Renaud; Marina Caillet; Mark Marsh; Clarisse Berlioz-Torrent
Journal:  PLoS Pathog       Date:  2011-02-03       Impact factor: 6.823

Review 10.  Modulation of HIV-1-host interaction: role of the Vpu accessory protein.

Authors:  Mathieu Dubé; Mariana G Bego; Catherine Paquay; Éric A Cohen
Journal:  Retrovirology       Date:  2010-12-22       Impact factor: 4.602

View more
  7 in total

1.  In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Authors:  Asa Rahimi; Gursev Anmole; Maribel Soto-Nava; Tania Escamilla-Gomez; Tristan Markle; Steven W Jin; Guinevere Q Lee; P Richard Harrigan; David R Bangsberg; Jeffrey Martin; Santiago Avila-Rios; Gustavo Reyes-Teran; Mark A Brockman; Zabrina L Brumme
Journal:  J Virol Methods       Date:  2016-11-16       Impact factor: 2.014

2.  HIV-1 Vpr redirects host ubiquitination pathway.

Authors:  Sakshi Arora; Sachin Verma; Akhil C Banerjea
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

3.  Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation.

Authors:  Susanna M Bächle; Daniel Sauter; Sabrina Sibitz; Johan K Sandberg; Frank Kirchhoff; Markus Moll
Journal:  Sci Rep       Date:  2015-04-15       Impact factor: 4.379

4.  Functional conservation and coherence of HIV-1 subtype A Vpu alleles.

Authors:  Bizhan Romani; Amirarsalan Kavyanifard; Elham Allahbakhshi
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

5.  Functional conservation and coherence of HIV-1 subtype A Vpu alleles.

Authors:  Bizhan Romani; Amirarsalan Kavyanifard; Elham Allahbakhshi
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

Review 6.  Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease.

Authors:  Siobhan Gargan; Nigel J Stevenson
Journal:  Viruses       Date:  2021-10-27       Impact factor: 5.048

7.  Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.

Authors:  Suzanne Pickering; Stephane Hué; Eun-Young Kim; Susheel Reddy; Steven M Wolinsky; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2014-01-23       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.